SCHEMBL25925913

SCHEMBL25925913

CSc1nsc(/N=N/c2ccc(O)cc2O)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.50
KMT2A Q03164 10/20 0.50
MAPT P10636 5/20 0.50
MAPK1 P28482 4/20 0.50
L3MBTL1 Q9Y468 4/20 0.50
POLB P06746 3/20 0.50
NPSR1 Q6W5P4 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
KDM4E B2RXH2 1/20 0.50
IDO1 P14902 1/20 0.50
TDO2 P48775 1/20 0.50
GFER P55789 1/20 0.50
EGFR P00533 1/20 0.45
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.37
HTT P42858 1/20 0.37
NSD2 O96028 2/20 0.35
MMP14 P50281 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25926084 0.84 KCNH2 (0.48) MEN1KMT2AMAPTMAPK1L3MBTL1
SCHEMBL25925915 0.81 MEN1 (0.54) MEN1KMT2AMAPTMAPK1L3MBTL1
SCHEMBL25925929 0.81 MEN1 (0.32) MEN1KMT2AMAPK1L3MBTL1TDP1
SCHEMBL25925923 0.81 L3MBTL1 (0.35) MEN1KMT2AMAPTMAPK1L3MBTL1
SCHEMBL24504356 0.79 KMT2A (0.33) MEN1KMT2AMAPTMAPK1L3MBTL1
SCHEMBL12795330 0.76 CYP1A2 (0.33) MEN1KMT2AL3MBTL1TSHRCYP1A2
SCHEMBL25925927 0.76 KMT2A (0.43) MEN1KMT2AMAPTMAPK1L3MBTL1
SCHEMBL24504568 0.75 PTGS2 (0.39) MEN1KMT2AMAPTMAPK1L3MBTL1
SCHEMBL25925868 0.75 HSP90AA1 (0.31) L3MBTL1HSP90AA1CCR6
SCHEMBL24504697 0.73 KMT2A (0.49) MEN1KMT2AMAPTMAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242523-A1 COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE FUJIFILM CORPORATION (JP) 2023-08-03 US disclosed
US-20230242523-A1 COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE FUJIFILM CORPORATION (JP) 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242523-A1 COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE AR, MAPT, NR5A1 MEN1 67/4885KMT2A 1814/4885MAPT 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.